Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Aptose Biosciences Inc (APTO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Aptose Biosciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.230 -0.040    -3.15%
19/04 - Closed. Currency in USD ( Disclaimer )
After Hours
1.230
-0.000
-0.000%
22:52:54 - Real-time Data
  • Volume: 36,211
  • Bid/Ask: 1.230 / 1.320
  • Day's Range: 1.230 - 1.285
Type:  Equity
Market:  United States
Aptose Biosciences 1.230 -0.040 -3.15%

Aptose Biosciences Company Profile

 
Read the Aptose Biosciences Inc company profile to learn more about the business and the management team. View Aptose Biosciences Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin’s lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Contact Information

Address 251 Consumers Road Suite 1105
Toronto, M2J 4R3
Canada
Phone 647 479 9828
Fax -

Top Executives

Name Age Since Title
Denis R. Burger 79 2007 Lead Independent Director
Mark David Vincent 70 2007 Independent Director
William G. Rice 64 2013 Chairman, President, CEO & Chief Accounting Officer
Warren Whitehead 71 2011 Independent Director
Stephen B. Howell 78 - Member of Scientific Advisory Board
Brian J. Druker 67 2013 Chairman of Scientific Advisory Board
Erich M. Platzer 73 2014 Independent Director
Daniel Douglas Von Hoff 75 2013 Member of Scientific Advisory Board
Michael Andreeff - 2015 Member of Scientific Advisory Board
Carol Gail Ashe 65 2018 Independent Director
Bernd Robert Seizinger 67 2022 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

APS Price Commentary

Write your thoughts about Aptose Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Liew ST
Liew ST Apr 15, 2021 0:47
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2021.03.04. Smarter Analyst $4. Tgt $14.0. Consensus $11.20
Liew ST
Liew ST Apr 06, 2021 15:11
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bought $3.97. Sold $6.66. Wait for it to drop further
Liew ST
Liew ST Mar 24, 2021 14:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2021.03.24.Sold @ $6.66. reached $7.20 earlier
Liew ST
Liew ST Mar 24, 2021 14:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bought $3.97
Liew ST
Liew ST Mar 04, 2021 16:25
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2021.03.04. Smarter Analyst $4. Tgt $14.0. Consensus $11.20
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email